Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Active not recruiting 3Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Non-Muscle Invasive Bladder Neoplasms 3Urinary Bladder Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Turcot syndrome 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Microsatellite Instability 1Melanoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 4BCG Vaccine 4Mitomycin 3ALT-803 3durvalumab 2dodecyl maltoside 2Docetaxel 2erdafitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Non-Muscle Invasive Bladder Neoplasms × ALT-803 × Clear all
NCT05981131 2026-04-29

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

ImmunityBio, Inc.

Active not recruiting
6 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT02138734 2026-03-31

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

ImmunityBio, Inc.

Phase 1/2 Active not recruiting
369 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT03022825 2025-10-16

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

ImmunityBio, Inc.

Phase 2/3 Active not recruiting
190 enrolled 1 FDA
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡